Dako to Develop Pharmacodiagnostic Tests for Bristol-Myers Squibb

Dako (Glostrup, Denmark) has entered into collaboration with Bristol-Myers Squibb (New York, NY, USA) to develop clinical diagnostics intended to identify cancer patients more likely to benefit from treatment with drug candidates.

Pharmacodiagnostics are increasing in demand with the recognition that personalized medicine may provide a way to improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies. Dako's goals are to improve tissue-based cancer diagnostics focusing on the workflow in the pathology laboratory. Its aim is to develop and market expertise, instruments, reagents, and software that will reduce time from biopsy to diagnosis, improve quality and reliability of the diagnosis and efficiency in the lab. It offers connected laboratory systems and ensures consistent, high-quality staining.

The new collaboration with Bristol-Myers Squibb recognizes Dako's position in the clinical diagnostics market and considers it a strong partner for developing diagnostic tests for use in conjunction with drug therapies.

"We are pleased to announce our collaboration with Bristol-Myers Squibb to develop these companion diagnostics that will expand the world-wide use of pharmDx assays. There is a growing need to identify those cancer therapies most effective for each patient. Dako's tests will be developed as companion products for specific Bristol-Myers Squibb investigational therapeutics. We believe it is important for pharmaceutical companies and diagnostic companies to combine their expertise into a strong collaborative approach to enable development of diagnostic tests for use with drug therapies,” said Patrik Dahlén, CEO and president of Dako Denmark.

Bristol-Myers Squibb is a global biopharmaceutic and healthcare products company.


Related Links:
Dako
Bristol-Myers Squibb